Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France
A study to estimate the overall survival in real-life conditions in France of adult participants treated with nivolumab in combination with chemotherapy as first-line treatment for gastric and gastroesophageal junction cancer.
Gastric Adenocarcinoma|Gastro-esophageal Junction Adenocarcinoma|Esophageal Adenocarcinoma (EAC)|Esophageal Squamous Cell Carcinoma (ESCC)
DRUG: nivolumab + chemotherapy
Overall survival (OS), Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36
Cause of death (where available), Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Disease progression, As assessed by the Site Investigator, Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Progression-free survival (PFS), Day 0 and months 2, 3, 4-6, 8-9, 12, 18, 24, 30 and 36|Time to treatment discontinuation (TTD), Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Time to failure of strategy (TFS), Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Time to next Treatment (TTNT), Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Second progression-free survival (PFS2), Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Treatment Free Interval (TFI), Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Overall tumor response (ORR), Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Response rate, Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Duration of response (DOR), Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Participant socio-demographics, Baseline|Participant clinical characteristics, Baseline|Participant treatment history, Baseline|Nivolumab treatment regime, Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Chemotherapy treatment regime, Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Reason for treatment discontinuation, Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Subsequent non-systemic treatment received post first-line treatment, Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Subsequent systemic treatment received post first-line treatment, Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Subsequent systemic treatment effectiveness, Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36|Participant adverse events (AEs), Up to 3 years|Participant health related quality of life as assessed by 5-level EuroQoL-5 dimension version (EQ-5D-5L), Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36
A study to estimate the overall survival in real-life conditions in France of adult participants treated with nivolumab in combination with chemotherapy as first-line treatment for gastric and gastroesophageal junction cancer.